• Aucun résultat trouvé

A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome

N/A
N/A
Protected

Academic year: 2021

Partager "A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome"

Copied!
9
0
0

Texte intégral

Loading

Figure

Table 1. Immunohistochemical and genetic characteristics of all cases All cases n (%) BLn (%) DLBCLn(%) Intermediate DLBCL/BLn(%) P value Total 242 (100.0) 22 (9.1) 193 (79.8) 27 (11.2) Age at diagnosis <0.001 Median 60.5 37.5 63 54 Mean 58.1 38.6 61.2
Table 2. Clinical characteristics of the patients
Figure 1. Results of immunohistochemical markers. ’CSE1L’ in reactive lymphoid tissue at (A) low (20×) and (B) high power (40×) magnification with predominant, cytoplasmic reactivity in germinal-center dark cells and less strong in the light zone, but not i
Figure 2. Decision trees trained to predict the diagnosis of either Burkitt’s lymphoma (BL) or diffuse large B-cell lymphoma (DLBCL) with different sets of markers and FISH results (n = 248)
+3

Références

Documents relatifs

Titre du livre J’ai lu Mon avis Score. Pôle Nord pôle Sud

Friedreich ataxia was considered as a diagnosis based on ataxia with a bilateral Babinski sign and absent Achilles reflexes and normal blood vitamin E levels with undetectable

(*) - Le risque relatif de chômage mesure le rapport entre la probabilité d'être au chômage et la probabilité d'être en emploi par rapport à une situation de référence : celle

[r]

En alimentation parentérale pédiatrique, il semble donc préférable d’utiliser l’huile de poisson pour le trai- tement de la cholestase associée à l’alimentation paren- térale

This non-potential field cannot be isolated using CHAMP total intensity field data and does not (and could not) appear in the results of the Malin (1973) analysis, because the

New England Journal of Medicine 2005;35212:1197-1205 7 Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive

The aggressive activated B-cell like ABC subtype of diffuse large B-cell lymphoma DLBCL exploits a multi-protein complex of CARMA1, BCL10 and MALT1 CBM complex, which normally